Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCALIBER maintenance study of iberdomide versus lenalidomide after autologous stem cell transplant in newly diagnosed multiple myeloma
MOH_2023-08-22_012864Phase 3Not yet recruiting
- Sponsor
- Celgene Corporation
- Start
- Apr 2023
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of iberdomide and lenalidomide in multiple myeloma (MM) (6 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
iberdomidelenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2023-08-22_012864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-22_012864.